ARTICLE | Finance
Coversin operations
How Celsus, Deerfield grabbed potential best-in-class complement inhibitor
August 24, 2015 7:00 AM UTC
A Deerfield-led investor group has pegged the value of a Phase Ia complement 5 (C5) inhibitor at $150 million and thinks the asset, Coversin, will have a dosing advantage over Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).
Coversin is owned by Geneva-based Volution Immuno Pharmaceuticals S.A., which is reverse-merging with Celsus Therapeutics plc (NASDAQ:CLTX) to form Akari Therapeutics plc (NASDAQ:AKTX). ...